🚨 Breaking: Efferocytosis – the immune system’s cleanup squad gone rogue in rheumatic diseases! Defects spark SLE, RA & more. Here’s the scoop in a thread: 🧵. 1) What is it? Phagocytes clear dead cells to dodge inflammation & autoimmunity. Mess up = disease chaos! 😱.2) Phases

🚨 Dermatomyositis Decoded: Skin Shenanigans, Immune Mayhem & Treatment Triumphs! @SpringerNature . 🔹 DM Spectrum Unleashed – From classic skin-muscle combo (heliotrope rash, Gottron’s papules) to amyopathic (skin-only) vibes. Watch for ILD, malignancy risks!

🚨 Viral Ghosts in Our DNA: How Ancient Retroelements Supercharge (or Sabotage) Immunity! Epic @ScienceMagazine review drops bombshells:. 🔹 Self vs. Invader Dilemma – Mammal defenses smash viruses but tiptoe around endogenous retroviruses (ERVs) & RTEs (42% of our genome!) to

RT @BS_Prasad: 8 minutes of Pure Bliss. 😍😍😍😍. "_She is Just Outstanding 👌🏾👌🏻_"

🚨 Anti-PCOLCE: New RA Biomarker Breakthrough! 🩺🔬.•RA Detection: 51.53% sensitivity, 93.60% specificity. 📊.•Seronegative Star: 40% positive in anti-CCP neg, 38.76% RF neg, 36.46% double-neg. 🛡️.•Power Combo: With anti-CCP, 82.14% sensitivity, 90.21% specificity. 💥.•Early.

🚨 Breaking Down Refractory Psoriatic Arthritis (PsA): The Stubborn Beast That Won’t Back Down! 🛡️ . •PsA Primer: Chronic inflammation hitting joints, skin, & more—heterogeneous nightmare affecting axial/peripheral spots. Multifactorial etiology makes it a puzzle! 🧩

2025 AHA/ACC Hypertension Guidelines: Top 10 Takeaways 🤟🏻. 1High BP: Major CVD Risk - Leading modifiable cause of heart disease, stroke, dementia, CKD, & mortality. Target: <130/80 mm Hg for most adults, using PREVENT™ for risk assessment. 2Community Screening - Clinicians +

🚨 New Atlas of Juvenile Idiopathic Arthritis (JIA) Synovium! 🌟.•Mapped inflamed joints in kids w/ JIA using single-cell RNA-seq, imaging & spatial tech—uncovering unique cell niches tied to disease severity. •SPP1+ macrophages & fibrin-linked myeloid cells host genes for

🚀 Breakthrough ELISA Detects Anti-NVL2 Autoantibodies!.•Targets NVL2 in SSc, IIP, SLE, & more: 18/1676 patients positive—largest cohort yet!.•17% of homogeneous nucleolar (AC-8) patterns show anti-NVL2. •Higher titers strongly linked to SSc diagnosis (p<0.042). •Found in.

🚨 New ACR Guidance on VEXAS Syndrome! .First international consensus for this rare hematoinflammatory disease. Key highlights:.🔹 Clinical Features: Men >50 yrs; fever, skin/eye/lung issues, macrocytic anemia, bone marrow vacuoles. Not heritable!.🔹 Diagnosis: Somatic UBA1

RT @AjHematology: Anti-ADAMTS13 antibodies trajectory is associated with ADAMTS13 recovery in immune-mediated #TTP..

🚨 RA & ILD Risk Unveiled! 🇰🇷 Large-scale study (2010-2017) exposes critical insights:. • RA patients: 8x higher ILD risk (aHR 7.84) vs. controls. • Seropositive RA: 9x risk (aHR 9.00); Seronegative: 5x (aHR 4.81). • SPRA > SNRA risk (sHR 1.90) – both need close ILD.

🚨 PTH Receptor Agonists: Game-Changers in Osteoporosis Management! 🚨. 🔥 PTH Basics: Intermittent dosing amps bone formation over resorption—unlike constant hyperparathyroidism vibes!.🔥 Teriparatide (PTH 1-34 analog): Boosts BMD (spine +13%, hip +3-4%); cuts vertebral

🚨 Breaking Down IBD-Associated Spondyloarthritis (IBD-SpA): The Gut-Joint Drama! 🚨. 🔥 Hits 10-20% of IBD folks (Crohn’s or UC)—no big diffs between CD-SpA & UC-SpA. 🔥 Joint Jams: Peripheral arthritis reigns (13%)—Type 1: Big joints flare with gut chaos; Type 2: Multi-joint

🔥 Unlocking the mystery of axial PsA vs axSpA: Same family, different vibes! 🦴💥. Epidemiology: Axial PsA strikes 4-70% of PsA folks (older, more women); axSpA (0.2-1.4%) loves younger folks & HLA-B27. 🧬.Pathogenesis: Both share genes, but axial PsA’s HLA-B27 is less frequent

🩺 ACG 2025 EoE (Eosinophilic Esophagitis )Guidelines: Must-Know Updates for Diagnosis & Management 💊.1Diagnosis 🔍: Confirm EoE with esophageal dysfunction symptoms + ≥15 eos/hpf on biopsy; rule out non-EoE causes. 2Endoscopy 📸: Use EREFS to score edema, rings, exudates,

🩺 JAK Inhibitors Fuel Thrombosis Risk in RA 💉.1🔴 RA’s Clot Risk: RA patients have 50–100% higher VTE risk (DVT, PE) due to chronic inflammation & disease activity. 2🟠 Tofacitinib Fails: Zavoriti & Miossec show tofacitinib cuts synovial/vascular inflammation but not IL-17/TNF.

🚨 Food Allergy Breakthrough! 🚨.CysLTs drive anaphylaxis in mice! .1CysLTs Trigger Anaphylaxis 😱.Move food allergens from gut to tissue, sparking severe reactions. 2DPEP1 Variants Protect 🛡️.Enhanced enzyme activity blocks CysLTs, preventing anaphylaxis. 3Mast Cells Shine 🌟

🦴 Cracking the Code on Osteoporosis in Axial Spondyloarthritis (r-axSpA) 🩺.1🔴 Silent Threat: r-axSpA patients face low-energy fractures (vertebral, femoral neck), crushing quality of life due to bone structure damage. 2🟠 BMD’s Blind Spot: Standard Bone Mineral Density (BMD)